Bolt Biotherapeutics, Inc.

As of March 30, 2022, Bolt Biotherapeutics, Inc. is considered a risky investment due to its overvaluation and negative performance metrics, including a P/E ratio of -0.1998 and a significant one-year return of -57.46%, compared to the S&P 500's gain of 17.14%.

As of March 30, 2022, Bolt Biotherapeutics is considered risky and overvalued due to its negative earnings, substantial losses, and poor performance, with a year-to-date decline of 47.67% compared to the S&P 500's gain of 2.44%.

As of June 11, 2025, the trend has shifted to mildly bearish due to bearish signals from moving averages and Bollinger Bands, despite some mixed indicators like a mildly bullish MACD and neutral RSI.

Bolt Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $11 million as of March 2025. Key financial metrics include a market cap of $10.81 million, a negative P/E ratio, and a debt-to-equity ratio of -0.80.

As of Jun 18, Bolt Biotherapeutics, Inc. has a market capitalization of 10.81 million, with net sales of 3.63 million and a net profit of -63.36 million over the latest four quarters. The company reported shareholder's funds of 57.20 million and total assets of 99.63 million as of Dec 24.